샘플 요청 목록

 카트 문의
시장보고서
상품코드
1781262

세계의 HIV 임상시험 시장

HIV Clinical Trials
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 379 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 HIV 임상시험 시장은 2030년까지 19억 달러에 이를 전망

2024년에 15억 달러로 추정되는 HIV 임상시험 세계 시장은 2024-2030년간 CAGR 4.3%로 성장하여 2030년에는 19억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 단계 I는 CAGR 3.2%를 나타내고, 분석 기간 종료시에는 9억 340만 달러에 이를 것으로 예측됩니다. 단계 II 부문의 성장률은 분석 기간에 CAGR 5.5%로 추정됩니다.

미국 시장은 4억 1,230만 달러로 추정, 중국은 CAGR7.6%로 성장 예측

미국의 HIV 임상시험 시장은 2024년에 4억 1,230만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 3억 9,420만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.6%로 추정됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.8%와 3.3%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.5%를 보일 전망입니다.

세계의 HIV 임상시험 시장 - 주요 동향과 촉진요인 정리

HIV 임상시험이 확대되는 이유는? 차세대 치료제 및 백신 개발 촉진

HIV 임상시험 시장은 연구자들이 지속형 항레트로바이러스제(ARV), 기능성 치료제, 예방 백신과 같은 혁신적인 치료법을 모색하면서 큰 진전을 이루고 있습니다. HIV가 여전히 전 세계 보건의 문제로 대두되고 있는 가운데, 임상시험은 신약의 제형 개발, 환자의 순응도 향상, 감염률 감소에 중요한 역할을 하고 있습니다. 정부, 제약사, 비영리단체는 환자의 삶의 질을 개선하고 약제 내성 문제를 해결할 수 있는 새로운 치료법을 개발하기 위해 HIV 연구에 대한 투자를 늘리고 있습니다.

첨단 기술은 어떻게 HIV 임상 연구를 강화하는가?

인공지능(AI), 유전체 시퀀싱, CRISPR 기반 유전자 편집의 통합은 HIV 임상시험을 변화시키고 있습니다. AI는 환자 모집, 바이오마커 식별, 예측 모델링에 사용되며, 유전자 치료 시험은 HIV 저수지의 장기적인 바이러스 억제 및 박멸 가능성을 탐색하고 있습니다. 또한, 코로나19에 사용된 것과 유사한 mRNA 기반 백신 플랫폼이 HIV 예방 백신의 유망한 후보로 떠오르고 있습니다.

시장 성장에 있어 정부의 이니셔티브와 세계 공동연구는 어떤 역할을 하고 있는가?

민관 파트너십과 UNAIDS, NIH, 게이츠 재단, 세계보건기구(WHO) 등의 자금 지원으로 HIV 임상연구가 가속화되고 있습니다. 각국 정부는 유망한 치료법의 승인 절차를 가속화하기 위해 규제 신속화 메커니즘을 도입하고 있으며, 임상시험의 다양화 노력은 다양한 인종과 지리적 집단을 종합적으로 대표할 수 있도록 보장하고 있습니다.

HIV 임상시험 시장의 성장 원동력은?

HIV 임상시험 시장의 성장은 전 세계 HIV 감염률 증가, 지속형 치료제에 대한 수요 증가, 백신 연구에 대한 지속적인 투자 등 여러 요인에 의해 이루어지고 있습니다. 바이러스 내성을 예방하기 위해 여러 유형의 약물을 사용하는 병용요법으로의 전환은 치료 순응도를 최적화하고 부작용을 줄이는 데 초점을 맞춘 임상시험으로 이어지고 있습니다. 또한, 주사제 및 이식형 ARV의 등장으로 환자들이 매일 복용하는 경구용 약물을 대체할 수 있는 대안을 찾으면서 임상 연구의 형태가 바뀌고 있습니다. 나노 의약품과 개인 맞춤형 의료의 개발은 부작용이 적고 바이러스 억제를 개선하는 표적 HIV 치료제의 개발을 더욱 촉진하고 있습니다. 이와 함께 노출 전 예방약(PrEP)이나 항체를 이용한 치료법 등 HIV 예방 전략도 연구자들이 감염률을 낮출 수 있는 새로운 접근법을 모색하는 가운데 임상시험에서 지지를 얻고 있습니다. 또한, 원격 의료, 원격 모니터링, 디지털 헬스 플랫폼으로 가능해진 분산형 임상시험 모델과 가상 임상시험 모델은 특히 HIV 발병률이 가장 높은 저자원 환경에서 환자 참여와 유지를 강화하고 있습니다. 생물 의학 연구의 지속적인 발전, 세계 자금 지원 및 기술 혁신으로 HIV 임상시험 시장은 지속적인 성장을 이룰 준비가 되어 있으며, 향후 몇 년 동안 기능적 치료법과 백신의 획기적인 진전을 달성하는 것이 최종 목표입니다.

부문

단계(단계 I, 단계 II, 단계 III, 단계 IV);임상시험 디자인(개입 시험 디자인, 관찰 시험 디자인, 확대 액세스 시험 디자인);스폰서(제약 및 바이오의약품 기업 스폰서, 비영리 단체 스폰서, 기타 스폰서)

조사 대상 기업 예

  • AbbVie Inc.
  • AIDS Clinical Trials Group(ACTG)
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Charles River Laboratories International, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc(ViiV Healthcare)
  • HIV Vaccine Trials Network(HVTN)
  • ICON plc
  • IQVIA Holdings Inc.
  • Janssen Pharmaceutical Companies(Johnson & Johnson)
  • Merck & Co., Inc.
  • Parexel International Corporation
  • Pfizer Inc.
  • PPD, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • SGS SA
  • Syneos Health
  • WuXi AppTec

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI툴에 의해서, 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.08.12

Global HIV Clinical Trials Market to Reach US$1.9 Billion by 2030

The global market for HIV Clinical Trials estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$903.4 Million by the end of the analysis period. Growth in the Phase II segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$412.3 Million While China is Forecast to Grow at 7.6% CAGR

The HIV Clinical Trials market in the U.S. is estimated at US$412.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$394.2 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global HIV Clinical Trials Market - Key Trends & Drivers Summarized

Why Are HIV Clinical Trials Expanding? The Push for Next-Generation Therapies & Vaccines

The HIV clinical trials market is witnessing significant advancements as researchers explore innovative therapies, including long-acting antiretrovirals (ARVs), functional cures, and preventive vaccines. With HIV still posing a global health challenge, clinical trials play a vital role in developing new drug formulations, enhancing patient compliance, and reducing transmission rates. Governments, pharmaceutical companies, and non-profit organizations are increasing investments in HIV research to develop novel treatment regimens that improve quality of life for patients and address drug resistance issues.

How Are Cutting-Edge Technologies Enhancing HIV Clinical Research?

The integration of artificial intelligence (AI), genomic sequencing, and CRISPR-based gene editing is transforming HIV clinical trials. AI is being used for patient recruitment, biomarker identification, and predictive modeling, while gene therapy trials are exploring potential long-term viral suppression or eradication of HIV reservoirs. Additionally, mRNA-based vaccine platforms, similar to those used for COVID-19, are emerging as promising candidates for preventive HIV vaccines.

What Role Do Government Initiatives & Global Collaborations Play in Market Growth?

Public-private partnerships and funding from organizations such as UNAIDS, the NIH, the Gates Foundation, and the World Health Organization (WHO) are accelerating HIV clinical research. Governments are introducing regulatory fast-tracking mechanisms to expedite approval processes for promising therapies, while clinical trial diversity efforts are ensuring inclusive representation of different ethnic and geographic populations.

What’s Driving the Growth of the HIV Clinical Trials Market?

The growth in the HIV clinical trials market is driven by multiple factors, including increasing global HIV prevalence, rising demand for long-acting therapies, and continued investment in vaccine research. The shift toward combination therapies-where multiple drug classes are used to prevent viral resistance-is leading to trials focused on optimizing treatment adherence and reducing side effects. Additionally, the rise of injectable and implantable ARVs is reshaping clinical research, as patients seek alternatives to daily oral medications. Advances in nanomedicine and personalized medicine are further supporting the development of targeted HIV treatments that improve viral suppression with fewer side effects. In parallel, HIV prevention strategies, including pre-exposure prophylaxis (PrEP) and antibody-based therapies, are gaining traction in clinical trials as researchers explore non-traditional approaches to reducing transmission rates. Furthermore, decentralized and virtual clinical trial models-enabled by telemedicine, remote monitoring, and digital health platforms-are enhancing patient participation and retention, particularly in low-resource settings where HIV incidence is highest. With continuous advancements in biomedical research, global funding support, and technological innovations, the HIV clinical trials market is poised for sustained growth, with the ultimate goal of achieving functional cures and vaccine breakthroughs in the coming years.

SCOPE OF STUDY:

The report analyzes the HIV Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Study Design (Interventional Study Design, Observational Study Design, Expanded Access Study Design); Sponsor (Pharmaceutical & Biopharmaceutical Companies Sponsor, Non-Profit Organizations Sponsor, Other Sponsors)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • AIDS Clinical Trials Group (ACTG)
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Charles River Laboratories International, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (ViiV Healthcare)
  • HIV Vaccine Trials Network (HVTN)
  • ICON plc
  • IQVIA Holdings Inc.
  • Janssen Pharmaceutical Companies (Johnson & Johnson)
  • Merck & Co., Inc.
  • Parexel International Corporation
  • Pfizer Inc.
  • PPD, Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • SGS SA
  • Syneos Health
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • HIV Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Ongoing Global HIV Burden Sustains High Clinical Research Activity and Funding
    • Emergence of Long-Acting Injectables and Implants Spurs Novel Trial Designs
    • Growing Focus on Functional Cure Research Drives Complex Multi-Arm Trial Structures
    • Shift Toward Decentralized and Virtual Trial Models Enhances Patient Accessibility
    • Use of AI and Genomics in Patient Stratification Optimizes Trial Outcomes
    • HIV Vaccine Candidates Entering Phase II/III Trials Expand the Therapeutic Landscape
    • Strategic Collaborations Between Pharma, Academia, and NGOs Strengthen R&D Pipelines
    • Regulatory Fast-Track and Breakthrough Designations Accelerate Development Timelines
    • Trials Targeting Viral Reservoirs and Latency Bring Next-Gen Therapies Into Focus
    • Mobile Health and Wearable Devices Enable Continuous Monitoring in Outpatient Trials
    • Pediatric and Adolescent Trial Inclusion Gains Importance in Line with WHO Guidelines
    • Integration of HIV Trials With Broader Infectious Disease Programs Expands Clinical Infrastructure
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HIV Clinical Trials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HIV Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HIV Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for HIV Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Sponsors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies Sponsor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pharmaceutical & Biopharmaceutical Companies Sponsor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pharmaceutical & Biopharmaceutical Companies Sponsor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Non-Profit Organizations Sponsor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Non-Profit Organizations Sponsor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Non-Profit Organizations Sponsor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Interventional Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Interventional Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Interventional Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Observational Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Observational Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Observational Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Expanded Access Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Expanded Access Study Design by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Expanded Access Study Design by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • JAPAN
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • CHINA
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • EUROPE
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for HIV Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for HIV Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for HIV Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • FRANCE
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • GERMANY
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for HIV Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for HIV Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for HIV Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • INDIA
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for HIV Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for HIV Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for HIV Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for HIV Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for HIV Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for HIV Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030
  • AFRICA
    • HIV Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for HIV Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for HIV Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for HIV Clinical Trials by Sponsor - Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for HIV Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Other Sponsors, Pharmaceutical & Biopharmaceutical Companies Sponsor and Non-Profit Organizations Sponsor for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for HIV Clinical Trials by Study Design - Interventional Study Design, Observational Study Design and Expanded Access Study Design Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for HIV Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional Study Design, Observational Study Design and Expanded Access Study Design for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제